The “2023 Retinal Pharmaceuticals Market Report” features new sales and disease prevalence forecasts through 2028. The report now covers adoption plans for complement inhibitors and new anti-VEGFs by ophthalmologists in the United States and Western Europe, as well as treatment patterns for anti-VEGFs. In addition, it includes IVT injection shares by drug in the United States and Western Europe.
The new report also evaluates more development-stage categories, therapies, and companies.
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.